Raymond C Regan

US Patent:

20130012443, Jan 10, 2013

Filed:

Jul 5, 2012

Appl. No.:

13/542046

Inventors:

Raymond F. Regan - Villanova PA, US

International Classification:

A61K 31/555
A61P 7/04
A61K 38/17
A61P 25/00
A61K 38/38
C07F 15/02

US Classification:

514 152, 514185, 540145, 514 153

Abstract:

Described herein are methods and compositions relating to treatment of tissue damage resulting from a central nervous system (CNS) hemorrhage with a protoporphyrin IX-Fe compound.

US Patent:

63294303, Dec 11, 2001

Filed:

Aug 18, 1999

Appl. No.:

9/376530

Inventors:

Raymond F. Regan - Wayne PA

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

A61K 31195

US Classification:

514562

Abstract:

The present invention involves a method of treating pain, neurological diseases and neuronal injury in a mammal by utilizing compounds that interact with and modify one of the redox sites of the N-methyl-D-aspartate (NMDA) receptor in said mammal. These compounds include S-substituted derivatives of glutathione which modulate or regulate the NMDA glutamate receptor.

US Patent:

56887973, Nov 18, 1997

Filed:

Apr 26, 1996

Appl. No.:

8/639908

Inventors:

Raymond F. Regan - Villanova PA
Edward H. Jasper - Ottsville PA

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

A61K 31495

US Classification:

514255

Abstract:

A method of treating patients suffering from acute trauma of the central nervous system is described. The method comprises identifying such patient and administering one or more piperazine derivative or mixtures thereof to said patient.

US Patent:

52093956, May 11, 1993

Filed:

May 23, 1991

Appl. No.:

7/704787

Inventors:

John Zouzoulas - West Chester PA
Raymond D. Regan - Downingtown PA
Robert Clauser - Coatesville PA

Assignee:

Mars Incorporated - McLean VA

International Classification:

G07B 1500
E05G 104

US Classification:

232 15

Abstract:

A method and apparatus for a lockable, removable cassette for attachment to a bill validator is disclosed. The cassette is removed from a bill validator by service personnel and transported to a central office, where an authorized person unlocks a hinged door with a separate key to remove stored bills. A lever is turned to a predetermined position which unlocks the cassette from the bill validator, and locks a pusher plate to prevent unauthorized bill removal. The lever is prevented from being turned clockwise and from further rotation past the predetermined position. When the hinged door of the secured cassette is opened by authorized personnel, the lever is released from its locked position arming the cassette. The emptied cassette can now be returned to the service person who can now reconnect it to a bill validator by further rotating the lever, which locks the cassette in place and unlocks the pusher plate to prepare the cassette to receive bills accepted by the validator. The cassette is easy to use, compact, tamper resistant, durable, and may use only mechanical parts.

US Patent:

20200338162, Oct 29, 2020

Filed:

Jul 7, 2020

Appl. No.:

16/922961

Inventors:

- Philadelphia PA, US
Raymond F. Regan - Villanova PA, US

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

A61K 38/17
G01N 33/68
A61P 7/10
A61P 39/06
A61P 25/00
A61P 29/00

Abstract:

A method for providing perihematomal protection to a patient after suffering an TCH comprising administering an effective amount of Hx to said patient to increase serum concentrations to between two and three times normal serum levels, wherein said increased serum concentrations are maintained for between and days.

US Patent:

20180185445, Jul 5, 2018

Filed:

Jun 13, 2016

Appl. No.:

15/735732

Inventors:

- Philadelphia PA, US
Raymond F. Regan - Villanova PA, US

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

A61K 38/17
G01N 33/68
A61P 25/00
A61P 29/00
A61P 7/10
A61P 39/06

Abstract:

A method for providing perihematomal protection to a patient after suffering an ICH comprising administering an effective amount of Hx to said patient to increase serum concentrations to between two and three times normal serum levels, wherein said increased serum concentrations are maintained for between 3 and 21 days.